Yarrow Bioscience, Inc. filed a Current Report on Form 8-K with the Securities and Exchange Commission on September 10, 2026. The filing discloses that the company has made available an investor presentation for general corporate and investor communications. A copy of this presentation, dated September 2026, is included as Exhibit 99.1 to the filing.
The filing also details an update to the company’s Annual Report on Form 10-K for the year ended December 31, 2025. This update reflects a merger between Yarrow Bioscience and Yarrow Bioscience Operating Company Corp., which was formerly known as Yarrow Bioscience, Inc. The revisions to the Annual Report are limited solely to this business update and do not affect the company’s previously reported results of operations, financial position, or cash flows.
According to the accompanying corporate presentation, Yarrow Bioscience is focused on developing novel therapies for thyroid autoimmune diseases. The company is advancing YB-101, a potential first-in-class anti-thyrotropin receptor (TSHR) antibody. Yarrow holds an exclusive license to YB-101 for the treatment of Graves’ Disease and Thyroid Eye Disease (TED) outside of greater China, granted by Changchun GeneScience Pharmaceutical Company, Ltd. in December 2025.
The company states that YB-101 is designed to directly and rapidly disrupt the central mechanism of Graves’ Disease and TED. It is formulated for subcutaneous administration with a dosing frequency of every eight weeks. Yarrow reports that it has raised $200 million to date from a syndicate of investors and expects its current cash resources to fund operations into 2028.
Regarding clinical development, Yarrow has initiated a Phase 2a/2b trial in Graves’ Disease in the second quarter of 2026. The company anticipates a Phase 2a proof-of-concept readout in the second half of 2027. Additionally, the company notes that it has received Fast Track Designation from the U.S. Food and Drug Administration for its Graves’ Disease program.
